

Company Update

Buy (maintained)

14 March 2018 – 5:30PM

MARKET PRICE: EUR3.24

TARGET PRICE: EUR3.92 (from EUR4.71)

Food & Beverage

Data

Shares Outstanding (m):	14.00
Market Cap. (EURm):	45.36
Enterprise Value (EURm):	110.57
Free Float (%):	37.8%
Av. Daily Trad. Vol. (m):	0.01
Main Shareholder:	Finanziaria Centrale del Latte di Torino 37.8%
Reuters/Bloomberg:	CLI.MI CLI IM
52-Week Range (EUR)	2.8 4.3

Source: Factset, UbiBanca estimates

Performance

	1m	3m	12m
Absolute	-2.1%	-2.9%	10.4%
Rel. to FTSE IT	-4.6%	-2.5%	-5.3%

Source: Factset

Graph area Absolute/Relative 12 M



Source: Factset

Marco Cristofori
Senior Analyst
marco.cristofori@ubibanca.it
Tel. +39 02 62753015

Financials

	2017	2018E	2019E	2020E
Revenues (EURm)	183.45	189.91	200.17	210.44
EBITDA (EURm)	7.24	9.91	11.85	13.04
EBITDA margin (%)	3.9%	5.1%	5.8%	6.1%
EBIT (EURm)	0.66	3.36	5.10	6.15
EPS (EUR)	-0.0	0.1	0.2	0.3
CFPS (EUR)	0.5	0.7	0.8	0.8
DPS (EUR)	0.0	0.0	0.1	0.1

Source: Company Data, UBI Banca Estimates

Sales in line but profitability weaker than expected in 4Q17

CLT reported sales in line with our forecasts in 4Q17 with organic growth of 3%, less than the 6% reported in the first nine months of the year due to decreasing raw milk prices. Organic growth for the full year of 4.1% confirmed the positive trend after years of stagnation, with good improvements for fresh milk, vegetable drinks and exports, which began to show the benefit of the partnership with Alibaba, partially offset by weaker revenues for yogurt, UHT milk and salads. The 4Q17 EBITDA margin of 4.6% (vs. 2.0% in 4Q16) was below our expectations. The full year net attributable result was negative for EUR0.3 million, also due to non-recurring expenses and higher D&A costs, while net debt increased to EUR62.4 million (vs. EUR60.2 million at Dec-16). The company will not distribute a dividend. We have revised our estimates (and introduced 2020 forecasts) decreasing our top line forecasts for 2018-19 (-5.5% on average) and EBITDA (-8.1% on average). Despite this downgrade to estimates, we reiterate our positive stance on the shares: CLT not only presents attractive market conditions (increasing demand for premium products and lower pricing pressure) and an expanded product range that includes new highly profitable niche sectors (for example, vegetable drinks and yogurt and vegan products) but is exploring new export markets and we see potential cost and cross-selling synergies stemming from the merger with CLT which are likely to emerge in the coming quarters.

- > Although results were below our expectations, we believe 2017 represented a major leap forward for CLI: the company gained market share in traditional products (7.6% in fresh milk vs. 7.3% in 2016), delivered strong growth in vegetable drinks and exports, improved its EBITDA margin (3.9% vs. 3.6% in 2016 on a pro-forma basis) and increased investments to upgrade its plants (almost EUR10 million vs. EUR4.2 million in 2016).
- > However, the speed of the recovery in profitability is somewhat below our expectations. This, coupled with declining milk prices (-15% since the beginning of 2018) has prompted us to reduce our estimates for 2018-19 (-8% on average at the EBITDA level).
- > Consequently, our target price has been reduced to EUR3.92 per share (from EUR4.71) implying potential upside of >20%. Buy confirmed.

Ratios

priced on 13 March 2018

	2017 *	2018E	2019E	2020E
P/E(x)	nm	25.9	15.0	11.9
P/CF(x)	7.1	5.5	4.6	4.2
P/BV(x)	0.7	0.7	0.7	0.6
Dividend Yield	0.0%	1.2%	2.2%	3.1%
EV/EBITDA(x)	15.4	11.2	9.2	8.2
Debt/Equity (x)	1.0	0.9	0.8	0.8
Debt/EBITDA (x)	8.6	5.9	4.8	4.2

Source: UBI Banca Estimates * Based on 2017 average price

Key Financials

(EURm)	2017	2018E	2019E	2020E
Revenues	183.45	189.91	200.17	210.44
EBITDA	7.24	9.91	11.85	13.04
EBIT	0.66	3.36	5.10	6.15
NOPAT	0.44	2.25	3.42	4.12
Free Cash Flow	-1.83	3.72	2.56	2.46
Net Capital Employed	125.48	123.51	123.98	125.34
Shareholders' Equity	63.10	64.85	67.32	70.15
Net Financial Position	62.38	58.66	56.66	55.18

Source: Company data, UBI Banca estimates

Key Profitability Drivers

	2017	2018E	2019E	2020E
Net Debt/Ebitda (x)	8.6	5.9	4.8	4.2
Net Debt/Equity (x)	1.0	0.9	0.8	0.8
Interest Coverage (%)	0.6	3.2	5.1	6.4
Free Cash Flow Yield (%)	-4.3%	8.2%	5.6%	5.4%
ROE (%)	-0.5%	2.7%	4.5%	5.4%
ROI pre-tax (%)	0.5%	2.4%	3.7%	4.4%
ROCE (%)	0.3%	1.6%	2.5%	3.0%

Source: Company data, UBI Banca estimates

Key Valuation Ratios

	2017 *	2018E	2019E	2020E
P/E (x)	nm	25.9	15.0	11.9
P/BV (x)	0.7	0.7	0.7	0.6
P/CF (x)	7.1	5.5	4.6	4.2
Dividend Yield (%)	0.0%	1.2%	2.2%	3.1%
EV/Sales (x)	0.6	0.6	0.5	0.5
EV/EBITDA (x)	15.4	11.2	9.2	8.2
EV/EBIT (x)	169.3	33.0	21.3	17.4
EV/CE (x)	0.9	0.9	0.9	0.9

Source: Company data, UBI Banca estimates

* Based on 2017 average price

Key Value Drivers

(%)	2017	2018E	2019E	2020E
Payout	0.0%	31.9%	32.3%	36.8%
NWC/Sales	3.5%	2.8%	2.2%	1.9%
Capex/Sales	5.0%	3.0%	4.0%	4.0%

Source: Company data, UBI Banca estimates

Recent Developments

- > In 2017 revenues increased 56% to EUR183.5 million but pro-forma revenues rose just 4.1% (as Centrale del Latte di Toscana was merged into CLI from October 2016), benefitting from the increase in selling prices (about 5%, introduced in June-17). Centrale del Latte di Torino increased revenues by 5.4%, Centrale del Latte di Vicenza by 10.8% and Centrale del Latte di Toscana by 4.7% based on our calculations. Sales by product are not significant as 2016 included CLT only in the last quarter of the year. However there was a sharp increase in fresh milk (+8.2%), vegetable drinks, exports and other products in 4Q17, which is a comparable period to 4Q16, while salads, yogurt, UHT and bulky milk declined.
- > Transport costs rose slightly (to 10.2% of value of production vs. 10.0% in 2016) and raw material costs increased to 52.6% of value of production (50.9% in 2016) due to the increase in fresh milk prices (the average spot price rose 21.8% compared to 2016). Labour costs declined to 14.0% vs. 15.2% of value of production in 2016. Non-recurring costs of EUR0.2 million, linked to management replacement, led to an EBITDA margin of 3.9% (vs. 3.6% in 2016 on a pro-forma basis) equating to an EBITDA margin of 4.1% excluding non-recurring costs.
- > After D&A of EUR6.6 million, slightly above our expectations, the operating profit was EUR0.7 million compared with an operating profit of EUR1.3 million in 2016 on a pro-forma basis. The Company substantially broke-even at the pre-tax level resulting in a negative bottom line of EUR0.3 million. This compares with a positive result of EUR12 million for 2016 which was sustained by a EUR13.9 million adjustment arising from the business combination (the difference between the assets acquired for EUR25.2 million and the fair value of the new shares issued for the business combination: EUR11.3 million). As in 2016, the company will not distribute a dividend.
- > Net debt increased to EUR62.4 million at Dec-17 (vs. EUR60.2 million at Dec-16) due to much higher capex (EUR9.5 million vs. EUR4.2 million in 2016) related to the upgrade of the plants of Florence and Vicenza. Gearing was 0.98x, the net debt/EBITDA ratio was 8.6x. Operating NWC was negative for EUR0.7 million with trade receivables at 64 days, trade payables at 84 days and inventories equal to 18 days. Fixed assets totalled EUR132 million and total net invested capital was EUR138.7 million, substantially stable compared with 2016 leading to a capital turnover of 1.32x.
- > Revenue growth was slower in 4Q17 (+3.0% vs. +6.0% in the first nine months of the year) while the EBITDA margin was 4.6% reflecting continuous quarter-on-quarter improvement (1.6% in 1Q17, 3.9% in 2Q17 and 5.4% in 3Q17) confirming the ability of the management to extract synergies from the merger with CLT, the improvement in the product mix and the positive impact of higher selling prices (mostly from 3Q17). It was, however, below our expectations. Higher D&A costs linked to the consolidation of CLT had an adverse impact on EBIT (EUR0.5 million vs. EUR1.3 million expected). The pre-tax result was EUR0.2 million in 4Q17.
- > At the end of November CLI completed the issue of a EUR15 million bond reserved for institutional investors which was fully subscribed. The bond has 5 years duration (expiry in December 2024) and a floating rate (Euribor 6 months plus a spread of 3.25%) and is expected to contribute to the investment programme of almost EUR15 million to upgrade CLI's main plant in Turin.
- > The trend in the milk market was positive in 2017 after years of stagnation: the

average spot price for raw milk soared by 21.8% (source: Assolatte) and volumes in Italy increased by 3.6% (4.5% in Piedmont, 3% in Veneto and 1.2% in Tuscany). Since the beginning of 2018, raw milk prices have declined by 15.1%, falling by 20% in March.

Figure 1 – 2017 results

(EURm)	2016A	2016A Pro-forma *	2017A	% Chg.	% Chg. vs. Pro-forma *	2017E UBI	% Chg.
Sales	117.88	176.20	183.45	55.6%	4.1%	184.96	-0.8%
Value of production	119.76	178.61	187.48	56.5%	5.0%	188.80	-0.7%
EBITDA	2.90	6.28	7.24	149.4%	15.3%	7.92	-8.5%
% margin	2.4%	3.5%	3.9%			4.2%	
EBIT	-1.61	1.30	0.66	nm		1.47	-55.0%
Pre tax	11.46		-0.31	nm		0.52	nm
Net attributable result	12.02		-0.26	nm		0.29	nm
Net debt/(cash)	60.23		62.38	3.6%		55.76	11.9%

Source: Company data, UBI Banca estimates * Pro-forma data assume the full consolidation of CLT

Figure 2 – 4Q17 results

(EURm)	4Q16A	4Q17A	% Chg.	4Q17E	% Chg.
Sales	46.08	47.44	3.0%	48.96	-3.1%
Value of production	47.18	48.69	3.2%	50.01	-2.6%
EBITDA	0.95	2.26	138.6%	2.94	-22.9%
% margin	2.0%	4.6%		5.9%	
EBIT	-0.86	0.51	nm	1.32	-61.1%
Pre tax	-0.83	0.20	nm	1.03	-80.9%
Net attributable result	-0.34	0.16	nm	0.70	-77.9%

Source: Company data, UBI Banca estimates

Figure 3 – 4Q17 and 2017 sales by product

(EURm, %)	4Q16A	4Q17A	% change	2016A *	2017A	% change
Fresh milk	19.0	20.5	8.2%	49.1	73.0	48.7%
UHT milk	10.8	5.4	-49.7%	24.1	38.7	60.5%
Yogurt	1.9	1.4	-27.8%	7.0	8.5	20.9%
Salads	1.4	1.3	-5.1%	5.9	6.3	6.9%
Vegetable drinks	0.5	0.8	67.1%	1.8	2.6	50.3%
Other products	11.0	16.1	45.9%	26.0	48.5	86.3%
Bulk milk	1.3	1.0	-27.4%	3.2	4.0	25.0%
Export	0.2	0.9	434.7%	0.8	1.9	128.5%
Total sales	46.1	47.4	3.0%	117.8	183.4	55.6%


Source: Company data

* 2016A include Centrale del Latte della Toscana only in 4Q16

Financial Projections

- > CLI stated that revenues grew by 3% in January 2018 and that the current year could be another year of consolidation with further cost efficiencies and the impact of the new organizational structure.
- > Since the beginning of the year the Italian fresh milk spot price has declined by 15% on average (to EUR0.32 per litre vs. EUR0.377) prompting us to reduce estimated organic growth to about 4.5% for 2018-19 from 7% previously expected. However, our growth projections are above the forecast trend for CLI's core market, due to our expectations of strong growth in revenues from vegetable drinks and exports. Our forecasts for fresh and UHT milk imply lower volumes but higher prices resulting in growth of about 1% p.a. In summary, we expect the top line to exceed EUR210 million in 2020 with a 2017-20 CAGR of 4.7%.
- > The company typically signs quarterly agreements with 150 farmers and sometimes purchases raw milk on the spot market. In this way, the company is partially protected from fluctuations in the price of raw milk, increasing its margin when the raw milk price rises but experiencing lower profitability if the raw milk price declines. Therefore, CLI's EBITDA could be adversely affected in the first part of 2018 but should benefit from lower fresh milk purchasing price in the longer term. We also expect a better product mix, cost efficiencies, economies of scale and operational leverage, leading to an EBITDA margin of 5.2% in 2018 (vs. 5.4% expected before), growing to >6.0% in 2020.
- > Lower EBITDA estimates coupled with higher D&A costs prompted an average decrease of EBIT forecasts for 2018-19 of about 18%. Consequently our 2018-19 bottom line forecasts have been cut by 22% on average.
- > CLI had net debt of EUR62.4 million at Dec-17, pushed up by higher than expected investments. In coming years, despite investment to restructure the Turin operations (EUR15 million in 2019-22 partly covered by a contribution from the Piedmont regional authorities), operating cash flow generation is expected to improve. We forecast a slight reduction in net debt to EUR58.6 million at Dec-18 and a further decline in 2019-20. We expect net debt of EUR56.7 million at Dec-19 and EUR55.2 million at Dec-20 excluding any new acquisitions.

Figure 4 – Spot price of milk in Italy: a four-year comparison



Source: Assolatte

Figure 5 – Old vs. New estimates

(EURm)	2017A	2018E		2019E		2020E
		Old	New	Old	New	New
Total Sales	183.45	199.36	189.91	213.63	200.17	210.44
% change			-4.7%		-6.3%	
EBITDA	7.24	10.68	9.91	13.03	11.85	13.04
% change			-7.2%		-9.0%	
EBIT	0.66	4.10	3.36	6.31	5.10	6.15
% change			-18.1%		-19.1%	
Net Profit	(0.26)	2.27	1.75	3.83	3.03	3.81
% change			-22.6%		-20.9%	
EPS	(0.02)	0.16	0.13	0.27	0.22	0.27
% change			-22.6%		-20.9%	
Net Debt/(Cash)	62.38	54.38	58.66	53.18	56.66	55.18
EBIT margin	0.4%	2.1%	1.8%	3.0%	2.5%	2.9%
EBITDA margin	3.9%	5.4%	5.2%	6.1%	5.9%	6.2%

Source: Company data, UBI Banca estimates

Figure 6 – 2014-2020E sales by product

(EURm)	2014	2015	2016	2017E	2018E	2019E	2020E	CAGR 17-20
Fresh milk	42.2	40.8	49.1	73.0	73.8	74.9	75.6	1.2%
UHT milk	20.7	18.5	24.1	38.7	39.2	39.6	40.2	1.3%
Yogurt	7.8	7.7	7.0	8.5	8.3	8.3	8.3	-0.8%
Salads	4.7	5.5	5.9	6.3	6.5	6.7	6.9	3.6%
Vegetable drinks	0.0	1.3	1.8	2.6	3.3	3.9	4.5	19.6%
Other products	20.3	19.5	26.0	48.7	51.2	56.3	61.1	7.8%
Bulk milk	3.8	2.8	3.2	4.0	4.1	4.2	4.4	3.5%
Export	0.9	0.9	0.8	1.9	3.5	6.2	9.4	72.0%
Total sales	100.4	97.0	176.2	183.7	189.9	200.2	210.4	4.6%

Source: Company data, UBI Banca estimates

Valuation

- > Given the revisions to our forecasts, our DCF valuation has decreased by 22% to EUR3.68 per share (from EUR4.74) and our relative valuation based on a sample of dairy producers to EUR3.83 per share from EUR4.15 per share. Our relative valuation based on two large multinational food producers (Danone and Nestlé), after applying a 30% discount to reflect the limited size of CLI and its minimal international exposure gives a fair value of EUR4.24 per share (EUR5.24 before). The simple average of our DCF and the relative valuations gives a target price of EUR3.92 (vs. EUR4.71 before) implying potential upside of >20% which supports our positive stance.
- > CLI is trading at a significant discount to its direct peers on EV/Sales (43% on average), mainly due to its smaller size. However, it trades at a premium on P/E and EV/EBITDA as it is penalised by its lower margins. We do not believe these multiples reflect the long-term potential of the company, which is expected to have a significant improvement in profitability in the future while other companies are expected to have stable profitability. In addition, CLI's current market capitalization (EUR45 million) is well below its net invested capital (EUR125 million at Dec-17) which implies that CLI would be a strong value destroyer in future. We believe this scenario is unlikely given the growing EBITDA expected for 2018-20 and the impact of the Turin plant upgrade which should improve profitability in the long run.
- > At our target price, Centrale del Latte d'Italia trades at 12.1x 2018 EV/EBITDA, which is above the median multiple of our peer sample of dairy product manufacturers (10.4x) but lower than Danone and Nestlé (12.5x and 13.9x respectively).

Figure 7 – Valuation summary

(EUR)		Weight	13-Nov 17	Delta
DCF Valuation	3.68	33.3%	4.74	-22.4%
Relative Valuation Dairy producers	3.83	33.3%	4.15	-7.6%
Relative Valuation Large multinationals (30% discount)	4.24	33.3%	5.24	-19.1%
Target price	3.92		4.71	-16.9%
Current price	3.24		3.67	-11.7%
Potential upside	20.8%		28.5%	

Source: UBI Banca estimates

Figure 8 – DCF Valuation

Our DCF valuation implies 12.3x EV/EBITDA at terminal value.

	(EUR m)	(% weight)
Sum of PV 2018-26 FCF	31.2	26%
Terminal value	89.1	74%
Total Enterprise value	120.3	100%
- Pension Provision	(6.5)	
- Net debt (+ cash)	(62.4)	
Total Equity value	51.5	
Fully diluted number of shares (m)	14.0	
Fair value per share (EUR)	3.68	

Source: UBI Banca estimates

Figure 9 – Dairy producers: peer comparison and valuation based on multiples (priced on 13 March 2018)

Company	Market Cap (EURm)	Country	P/E			EV/EBITDA			EV/Sales		
			2018E	2019E	2020E	2018E	2019E	2020E	2018E	2019E	2020E
Parmalat	5,621	Italy	24.8 x	21.6 x		9.4 x	8.3 x		0.7 x	0.7 x	
Dean Foods Company	683	US	13.8 x	11.7 x	12.4 x	5.6 x	5.1 x	4.9 x	0.24 x	0.24 x	0.24 x
Dairy Crest Group	875	UK	14.0 x	13.5 x		10.4 x	10.6 x		2.13 x	2.09 x	
Saputo	9,974	Canada	18.8 x	17.0 x		12.0 x	10.8 x		1.26 x	1.18 x	
Emmi	3,608	Switzerland	21.8 x	22.0 x	20.7 x	12.4 x	11.5 x	10.8 x	1.27 x	1.21 x	1.15 x
Average			18.6 x	17.2 x	16.6 x	10.0 x	9.3 x	7.9 x	1.13 x	1.08 x	0.69 x
Median			18.8 x	17.0 x	16.6 x	10.4 x	10.6 x	7.9 x	1.26 x	1.18 x	0.69 x
CLI current market multiples	45		25.9 x	15.0 x	11.9 x	11.2 x	9.2 x	8.2 x	0.57 x	0.53 x	0.50 x
Premium (discount) to average			38.9%	-12.9%	-28.2%	11.9%	-1.2%	4.4%	-49.4%	-50.7%	-28.2%
Valuation based on median (EUR)			2.35	3.69	4.51	3.14	4.96	3.40	12.92	12.79	6.50

Source: Factset, UBI Banca estimates

Figure 10 – Large multinationals: peer comparison and valuation based on multiples (priced on 13 March 2018)

Company	Market Cap (EURm)	Country	P/E			EV/EBITDA			EV/Sales		
			2018E	2019E	2020E	2018E	2019E	2020E	2018E	2019E	2020E
Danone	45,434	France	18.1 x	16.5 x	15.0 x	12.6 x	11.4 x	10.5 x	2.38 x	2.21 x	2.09 x
Nestlé	203,689	Switzerland	19.9 x	18.3 x	16.6 x	14.0 x	13.2 x	12.4 x	2.82 x	2.75 x	2.67 x
Average			19.0 x	17.4 x	15.8 x	13.3 x	12.3 x	11.4 x	2.60 x	2.48 x	2.38 x
CLI current market multiples	45		25.5 x	14.8 x	11.8 x	11.1 x	9.1 x	8.2 x	0.57 x	0.53 x	0.50 x
Premium (discount) to average			34.3%	-15.0%	-25.6%	-16.5%	-26.1%	-28.4%	-78.2%	-78.7%	-79.1%
Valuation based on average (EUR)			2.38	3.77	4.30	5.22	6.40	6.71	31.03	31.41	31.85

Source: Factset, UBI Banca estimates

Figure 11 – Implicit multiples based on our EUR3.92 target price

(x)	2018E	2019E	2020E
P/E	31.30 x	18.10 x	14.41 x
EV/EBITDA	12.11 x	9.97 x	8.95 x
EV/EBIT	35.79 x	23.18 x	18.98 x
EV/Sales	0.62 x	0.58 x	0.54 x
P/BV	0.85 x	0.82 x	0.78 x
EV/ Capital employed	0.97 x	0.95 x	0.93 x

Source: UBI Banca estimates

Income Statement

(EURm)	2017	2018E	2019E	2020E
Value of production	187.48	194.07	204.44	214.85
EBITDA	7.24	9.91	11.85	13.04
EBITDA margin	3.9%	5.1%	5.8%	6.1%
EBIT	0.66	3.36	5.10	6.15
EBIT margin	0.4%	1.7%	2.5%	2.9%
Net financial income /expense	-1.00	-0.85	-0.77	-0.71
Associates & Others	0.00	0.00	0.00	0.00
Profit before taxes	-0.34	2.51	4.33	5.44
Taxes	0.05	-0.75	-1.30	-1.63
Minorities & discontinuing ops	0.00	0.00	0.00	0.00
Net Income	-0.29	1.75	3.03	3.81

Source: Company data, UBI Banca estimates

Balance Sheet

(EURm)	2017	2018E	2019E	2020E
Net working capital	6.63	5.34	4.58	4.26
Net Fixed assets	132.10	132.12	134.45	137.07
M/L term funds	-13.25	-13.83	-14.42	-15.02
Capital employed	125.48	123.64	124.61	126.31
Shareholders' equity	63.10	64.84	67.37	70.21
Minorities	0.00	0.00	0.00	0.00
Shareholders' funds	63.10	64.84	67.37	70.21
Net financial debt/(cash)	62.38	58.80	57.24	56.10

Source: Company data, UBI Banca estimates

Cash Flow Statement

(EURm)	2017	2018E	2019E	2020E
NFP Beginning of Period	60.23	62.38	58.80	57.24
Group Net Profit	-0.29	1.75	3.08	3.82
Minorities	0.00	0.00	0.00	0.00
D&A	6.37	6.56	6.75	6.89
Change in Funds & TFR	0.00	0.00	0.00	0.00
Gross Cash Flow	6.08	8.30	9.84	10.71
Change In Working Capital	1.55	1.29	0.77	0.32
Other	0.00	0.00	0.00	0.00
Operating Cash Flow	7.63	9.59	10.60	11.03
Net Capex	-9.46	-6.01	-8.49	-8.91
Other Investments	0.00	0.00	0.00	0.00
Free Cash Flow	-1.83	3.59	2.11	2.12
Dividends Paid	0.00	0.00	-0.56	-0.98
Other & Chg in Consolid. Area	-0.35	0.00	0.00	0.00
Chg in Net Worth & Capital Incr.	0.00	0.00	0.00	0.00
Change in NFP	-2.18	3.59	1.55	1.14
NFP End of Period	62.41	58.80	57.24	56.10

Source: Company data, UBI Banca estimates

Financial Ratios

(%)	2017	2018E	2019E	2020E
ROE	-0.5%	2.7%	4.6%	5.4%
ROI	0.3%	1.6%	2.5%	3.0%
Net Fin. Debt/Equity (x)	1.0	0.9	0.8	0.8
Net Fin. Debt/EBITDA (x)	8.6	5.9	4.8	4.3
Interest Coverage	0.6	3.2	5.2	6.4
NWC/Sales	3.5%	2.7%	2.2%	1.9%
Capex/Sales	-5.0%	-3.0%	-4.0%	-4.0%
Pay Out Ratio	-0.0%	32.1%	31.8%	36.6%

Source: Company data, UBI Banca estimates

Per Share Data

(EUR)	2017	2018E	2019E	2020E
EPS	-0.02	0.13	0.22	0.27
DPS	0.00	0.04	0.07	0.10
Op. CFPS	0.54	0.68	0.77	0.79
Free CFPS	-0.13	0.27	0.18	0.18
BVPS	4.51	4.63	4.81	5.01

Source: Company data, UBI Banca estimates

Stock Market Ratios

(x)	2017	2018E	2019E	2020E
P/E	0.0	26.0	14.7	11.9
P/OpCFPS	5.6	4.7	4.3	4.1
P/BV	0.7	0.7	0.7	0.6
Dividend Yield (%)	0.0%	1.2%	2.2%	3.1%
Free Cash Flow Yield (%)	-4.3%	7.9%	4.7%	4.7%
EV (EURm)	111.73	110.57	109.22	108.15
EV/Sales	0.6	0.6	0.5	0.5
EV/EBITDA	15.4	11.2	9.2	8.3
EV/EBIT	169.3	33.1	21.1	17.5
EV/Capital Employed	0.9	0.9	0.9	0.9

Source: Company data, UBI Banca estimates

* Based on 2016 average price

Growth Rates

(%)	2017	2018E	2019E	2020E
Growth Group Net Sales	56.5%	3.5%	5.3%	5.1%
Growth EBITDA	149.4%	36.9%	19.6%	10.0%
Growth EBIT	nm	408.4%	51.9%	20.6%
Growth Net Profit	nm	nm	72.9%	25.6%

Source: Company data, UBI Banca estimates

Disclaimer

Analyst Declaration

This research report (the "Report") has been prepared by Marco Cristofori on behalf of UBI Banca S.p.A. ("UBI Banca") in the context of the ancillary service provided by UBI Banca named "Investment research and financial analysis or other forms of recommendation relating to transactions in financial instruments" under Paragraph 5), Section B, Annex I of the Directive 2014/65/EU ("MiFID II"). UBI Banca is an Italian bank under art. 4 (1)(27) of MiFID II and it is supervised by the European Central Bank and duly authorised to provide investment services pursuant to Article 1, Paragraph 5, letter a), b), c), c-bis), e) and f) of the Legislative Decree 24 February 1998, n° 58 under the supervision of the Italian Authority for the financial markets (Consob). UBI Banca has its head office at Piazza Vittorio Veneto 8, 24122 Bergamo.

The analyst who prepared the Report, and whose name and role appear on the front page, certifies that:

- a. The views expressed on the company, mentioned herein (the "Company") accurately reflect his personal views, but does not represent the views or opinions of UBI Banca, its management or any other company which is part of or affiliated with UBI Banca group (the "UBI Banca Group"). It may be possible that some UBI Banca Group officers may disagree with the views expressed in this Report;*
- b. He has not received, and will not receive any direct or indirect compensation in exchange for any views expressed in this Report;*
- c. The analyst does not own any securities and/or any other financial instruments issued by the Company or any financial instrument which the price depends on, or is linked to any securities and/or any financial instruments issued by the Company.*
- d. Neither the analyst nor any member of the analyst's household serves as an officer, director or advisory board member of the Company.*
- e. The remuneration of the analyst is not directly tied to transactions for services for investment firms or other types of transactions it or any legal person, part of the same group performs, or to trading fees it or any legal person that is part of the same group receives.*
- f. The analyst named in this document is a member of AIAF.*

General disclosure

This Report is for information purposes only. This Report (i) is not, nor may it be construed, to constitute, an offer for sale or subscription or of a solicitation of any offer to buy or subscribe for any securities issued or to be issued by the Company, (ii) should not be regarded as a substitute for the exercise of the recipient's own judgement. In addition, the information included in this Report may not be suitable for all recipients. Therefore the recipient should conduct their own investigations and analysis of the Company and securities referred to in this document, and make their own investment decisions without undue reliance on its contents. Neither UBI Banca, nor any other company belonging to the UBI Banca Group, nor any of its directors, managers, officers or employees, accepts any direct or indirect liability whatsoever (in negligence or otherwise), and accordingly no direct or indirect liability whatsoever shall be assumed by, or shall be placed on, UBI Banca, or any other company belonging to the UBI Banca Group, or any of its directors, managers, officers or employees, for any loss, damage, cost, expense, lower earnings howsoever arising from any use of this Report or its contents or otherwise arising in connection with this Report.

The information provided and the opinions expressed in this Report are based upon information and data provided to the public by the Company or news otherwise public, and refers to the date of publication of the Report. The sources (press publications, financial statements, current and periodic releases, as well as meetings and telephone conversations with the Company's representatives) are believed to be reliable and in good faith, but no representation or warranty, express or implied, is made by UBI Banca as to their accuracy, completeness or correctness. Past performance is not a guarantee of future results. Any opinions, forecasts or estimates contained herein constitute a judgement as of the date of this Report, and there can be no assurance that the future results of the Company and/or any future events involving directly or indirectly the Company will be consistent with any such opinions, forecasts or estimates. Any information herein is subject to change, update or amendment without notice by UBI Banca subsequent to the date of this Report, with no undertaking by UBI Banca to notify the recipient of this Report of such change, update or amendment.

Organizational and administrative arrangements to prevent conflicts of interests

UBI Banca maintains procedures and organizational mechanism (physical and non physical barriers designed to restrict the flow of information between the unit which performs investment research activity, and other units of UBI Banca) to prevent and professionally manage conflicts of interest in relation to investment research in accordance with art. 23 of Directive 2014/65/EU and under art. 34 (3) and art. 37 of the Regulation 2017/565/EU.

More specifically, UBI Banca has established, implements and maintains an effective conflicts of interests policy aimed at preventing and managing the potential conflicts of interest that could occur during the performance of the investment research services.

Insofar as the above mentioned organizational and administrative arrangements established by UBI Banca to prevent or manage potential conflicts of interests are not sufficient to ensure, with reasonable confidence, that risks of damage to the interests of the client will be prevented, UBI Banca engages to provide a clear disclosure of the specific conflicts of interests arising from the performance of investment research services, including a description of the sources of those conflicts and the steps undertaken to mitigate them, taking into account the nature of the client to whom the disclosure is being made.

For further information please see UBI Banca's website (www.ubibanca.com/equity-research - "Informativa sintetica sull'attività di ricerca") and (www.ubibanca.com/Mifid - "Policy sintetica conflitti di interessi"). More details about the conflicts of interests policy will be provided by UBI Banca upon request.

Disclosure of interests and conflicts of interests pursuant to Delegated Regulation 2016/958/EU

In relation to the Company the following interest/conflict of interest have been found:

- > UBI Banca acts as Corporate Broker for Centrale del Latte d'Italia.
- > UBI Banca may have long or short positions with the issuer

On the basis of the checks carried out no other interest/conflict of interest arose.

Frequency of updates

UBI Banca aims to provide continuous coverage of the companies in conjunction with the timing of periodical accounting reports and any exceptional event that occurs affecting the issuer's sphere of operations and in any case at least twice per year. The companies for

which UBI Banca acts as Sponsor or Specialist are covered in compliance with regulations of the market authorities.

For further information please refer to www.ubibanca.com/equity-research

Valuation methodology

UBI Banca's analysts value the Company subject to their recommendations using several methods among which the most prevalent are: the Discounted Cash Flow method (DCF), the Economic Value Added method (EVA), the Multiple comparison method, the SOP method and the NAV method.

The analysts use the above valuation methods alternatively and/or jointly at their discretion. The assigned target price may differ from their fair value, as it also takes into account overall market/sector conditions, corporate/market events, and corporate specifics (i.e. holding discounts) reasonably considered to be possible drivers of the company's share price performance. These factors may also be assessed using the methodologies indicated above.

For further information please refer to www.ubibanca.com/equity-research.

Ranking system

UBI Banca's analysts use an "absolute" rating system, not related to market performance. The explanation of the rating system is listed below:

Buy: if the target price is 10% higher than the market price, over the next 12 months.

Hold: if the target price is 10% below or 10% above the market price, over the next 12 months.

Sell: if the target price is 10% lower than the market price, over the next 12 months.

No Rating: the investment rating and target price have been suspended as there is not sufficient fundamental basis for determining an investment rating or target. The previous investment rating and target price, if any, are no longer in effect. Alternatively, No Rating is assigned in certain circumstances when UBI Banca is acting in any advisory capacity in a strategic transaction involving the Company.

Target price: the market price that the analyst believes that the share may reach within a one-year time horizon.

Market price: closing price on the day before the issue date of the report, appearing on the first page.

Distribution

Italy: This document is intended for distribution in electronic form to "Professional Clients" and "Qualified Counterparties" as defined by Legislative Decree 24 February 1998, n. 58 and by Consob Regulation n. 16190 dated 29.10.2007, as further amended and supplemented.

This Report has been released within 30 minutes from the timing reported on the front page.

IN THE UNITED KINGDOM, THIS DOCUMENT IS BEING DISTRIBUTED ONLY TO, AND IS DIRECTED ONLY AT PERSONS WHO (A) ARE (I) PERSONS FALLING WITHIN ARTICLE 19 OR ARTICLE 49 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (AND ONLY WHERE THE CONDITIONS CONTAINED IN THOSE ARTICLES HAVE BEEN, OR WILL AT THE RELEVANT TIME BE, SATISFIED) OR (II) ANY OTHER

PERSONS TO WHOM IT MAY BE LAWFULLY COMMUNICATED; AND (B) ARE QUALIFIED INVESTORS WITHIN THE MEANING OF ARTICLE 2(1)(E) OF THE PROSPECTUS DIRECTIVE (DIRECTIVE 2003/71/EC), (ALL SUCH PERSONS BEING REFERRED TO AS "RELEVANT PERSONS"). THIS DOCUMENT MUST NOT BE ACTED ON OR RELIED ON BY PERSONS WHO ARE NOT RELEVANT PERSONS.

Copyright

This Report is being supplied solely for the recipient's information and may not be reproduced, redistributed or passed on, directly or indirectly to any other person or published, in whole or in part, for any purpose without prior written consent of UBI Banca.

The copyright and intellectual property rights on the data are owned by UBI Banca Group, unless otherwise indicated. The data, information, opinions and valuations contained in this Report may not be subject to further distribution or reproduction, in any form or via any means, even in part, unless expressly consented by UBI Banca.

By accepting this Report the recipient agrees to be bound by all of the forgoing provisions.

Distribution of ratings

Equity rating dispersion in the past 12 months

Buy	Hold	Sell	No Rating
80.5%	9.8%	0.0%	9.8%

Proportion on issuers to which UBI Banca has supplied investment banking services relating to the last 12 months

Buy	Hold	Sell	No Rating
100%	100%	-	100%

For further information regarding yearly and quarterly rating statistics and descriptions, please refer to www.ubibanca.com/equity-research.

Historical ratings and target prices

Date	Rating	Target Price (EUR)	Market Price (EUR)
13 November 2017	Buy	4.71	3.67